AXIM Biotechnologies, Inc. Share Price Other OTC
Equities
AXIM
US05463V1008
Biotechnology & Medical Research
Sales 2022 | 8.88K 701K | Sales 2023 | 39.52K 3.12M | Capitalization | 4.52M 357M |
---|---|---|---|---|---|
Net income 2022 | -6M -474M | Net income 2023 | -8M -632M | EV / Sales 2022 | 1,218 x |
Net Debt 2022 | 5.64M 446M | Net Debt 2023 | 5.74M 453M | EV / Sales 2023 | 259 x |
P/E ratio 2022 |
-0.69
x | P/E ratio 2023 |
-0.48
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.42% |
Managers | Title | Age | Since |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 28/06/16 |
Kurt Phinney
COO | Chief Operating Officer | - | 22/05/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 17/05/17 |
Director/Board Member | 76 | 17/05/17 |
1st Jan change | Capi. | |
---|---|---|
+26.60% | 49.18B | |
+1.12% | 42.11B | |
+50.18% | 40.37B | |
-5.26% | 28.85B | |
+13.18% | 26.09B | |
-21.99% | 18.71B | |
+8.33% | 13.26B | |
+31.94% | 12.32B | |
+0.22% | 11.99B |